Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence
- 31 January 2016
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 47 (2) , 394-402
Abstract
Systematic review of the available scientific evidence on the role of bedaquiline in new effective M/XDR-TB regimenshttp://ow.ly/V68ZFKeywords
This publication has 58 references indexed in Scilit:
- Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosisEuropean Respiratory Journal, 2013
- Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary TuberculosisAntimicrobial Agents and Chemotherapy, 2013
- Old ideas to innovate tuberculosis control: preventive treatment to achieve eliminationEuropean Respiratory Journal, 2013
- Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosisEuropean Respiratory Journal, 2012
- Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TBEuropean Respiratory Journal, 2012
- Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 PatientsPLOS Medicine, 2012
- Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, IndiaPLOS ONE, 2012
- New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the FutureThe Journal of Infectious Diseases, 2012
- Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in MinskEuropean Respiratory Journal, 2011
- Genetic Basis for Natural and Acquired Resistance to the Diarylquinoline R207910 in MycobacteriaAntimicrobial Agents and Chemotherapy, 2006